Clinical Usefulness of Arbekacin

Lee, Jae Hoon; Lee, Chang Seop

doi:10.3947/ic.2016.48.1.1

Cited by 11 publications

(6 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, grade 2 or higher acute renal failure (13.6%) and elevated transaminase levels (9.1%) were observed. The reported frequencies of renal dysfunction and hepatic dysfunction are 0.0 - 23.1% and 0.85 - 8.5%, respectively [ 35 ], which are comparable to the results of the present study.…”

Section: Discussionsupporting

confidence: 91%

Clinical Efficacy and Safety of Arbekacin against Pneumonia in Febrile Neutropenia: A Retrospective Study in Patients with Hematologic Malignancies

Ohashi¹,

Fujita²,

Irisawa³

et al. 2022

Infect Chemother

View full text Add to dashboard Cite

Background Arbekacin (ABK) is an aminoglycoside that exhibits anti-methicillin-resistant Staphylococcus aureus (MRSA) and anti- Pseudomonas aeruginosa activities. Therefore, for patients with febrile neutropenia (FN) and concurrent pneumonia suspected to be caused by MRSA, ABK may be sufficiently effective even as a single agent. Materials and Methods Patients with hematologic malignancies treated with ABK who met the following criteria were included: 1) fever during neutropenia or functional neutropenia, 2) FN complicated by pneumonia, and 3) possible infection by antimicrobial-resistant Gram-positive cocci. Results This study encompassed 22 episodes involving 19 patients, of which, 15 (68.2%) were successfully treated with ABK. Of the nine episodes showing inadequate response to other anti-MRSA drugs, eight were successfully treated with ABK. Grade 2 or worse adverse events included acute kidney injury (13.6%) and increased transaminase levels (9.1%). Conclusion The present study demonstrated that ABK is effective and safe in patients with FN and concurrent pneumonia caused by antimicrobial-resistant Gram-positive cocci. ABK may also be effective in patients who are unresponsive to other anti-MRSA drugs. Therefore, ABK may be beneficial in the treatment of pneumonia caused by antimicrobial-resistant Gram-positive cocci in patients with FN.

show abstract

Section: Discussionsupporting

confidence: 91%

Clinical Efficacy and Safety of Arbekacin against Pneumonia in Febrile Neutropenia: A Retrospective Study in Patients with Hematologic Malignancies

Ohashi¹,

Fujita²,

Irisawa³

et al. 2022

Infect Chemother

View full text Add to dashboard Cite

show abstract

“…The drug arbekacin is efficacious towards gram-positive bacteria, and methicillin-resistant Staphylococcus aureus , without any chronic, dangerous, or life-threatening adverse events. It is efficacious when administered as inhalation in patients with pneumonia caused by P. aeruginosa and MRSA ( Lee and Lee, 2016 ). Dequalinium chloride is an antimicrobial agent generally used for skin and vagina ( Mendling et al, 2016 ).…”

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study

Baby

Maity

Mehta

et al. 2021

European Journal of Pharmacology

View full text Add to dashboard Cite

The coronavirus disease (COVID-19) is spreading between human populations mainly through nasal droplets. Currently, the vaccines have great hope, but it takes years for testing its efficacy in human. As there is no specific drug treatment available for COVID-19 pandemic, we explored in silico repurposing of drugs with dual inhibition properties by targeting transmembrane serine protease 2 (TMPRSS2) and human angiotensin-converting enzyme 2 (ACE2) from FDA-approved drugs. The TMPRSS2 and ACE2 dual inhibitors in COVID-19 would be a novel antiviral class of drugs called “entry inhibitors.” For this purpose, approximately 2800 US-FDA approved drugs were docked using a virtual docking tool with the targets TMPRSS2 and ACE2. The best-fit drugs were selected as per docking scores and visual outcomes. Later on, drugs were selected on the basis of molecular dynamics simulations. The drugs alvimopan, arbekacin, dequalinum, fleroxacin, lopinavir, and valrubicin were shortlisted by visual analysis and molecular dynamics simulations. Among these, lopinavir and valrubicin were found to be superior in terms of dual inhibition. Thus, lopinavir and valrubicin have the potential of dual-target inhibition whereby preventing SARS-CoV-2 entry to the host. For repurposing of these drugs, further screening in vitro and in vivo would help in exploring clinically.

show abstract

“…Semisynthetic derivatives have since been developed to improve the pharmacological profile (Tod et al 2000 ) and combat antimicrobial resistance (Krause et al 2016 ), and examples include amikacin (Kawaguchi et al 1972 ), netilmicin (Miller et al 1976 ), isepamicin (Nagabhushan et al 1978 ), arbekacin (Kondo et al 1973 ), etimicin (Fan et al 1995 ), and plazomicin (Aggen et al 2010 ). Aminoglycosides entered widespread clinical use to combat infections caused by members of the Enterobacterales order of Gram-negatives including Escherichia coli and Klebsiella pneumonia (Krause et al 2016 ), and they have also been used effectively against Pseudomonas aeruginosa (Karlowsky et al 2003 ) and Staphylococcus aureus (Lee and Lee 2016 ). Alternative broad-spectrum antibiotics were developed in the 1970 and 1980 s that exhibited reduced toxicity compared to aminoglycosides (Becker and Cooper 2013 ), including fluoroquinolones, β-lactams combined with β-lactamase inhibitors, cephalosporins and carbapenems.…”

Section: Introductionmentioning

confidence: 99%

A mini-review: environmental and metabolic factors affecting aminoglycoside efficacy

Webster

Shepherd

2022

World J Microbiol Biotechnol

View full text Add to dashboard Cite

Following the discovery of streptomycin from Streptomyces griseus in the 1940s by Selman Waksman and colleagues, aminoglycosides were first used to treat tuberculosis and then numerous derivatives have since been used to combat a wide variety of bacterial infections. These bactericidal antibiotics were used as first-line treatments for several decades but were largely replaced by ß-lactams and fluoroquinolones in the 1980s, although widespread emergence of antibiotic-resistance has led to renewed interest in aminoglycosides. The primary site of action for aminoglycosides is the 30 S ribosomal subunit where they disrupt protein translation, which contributes to widespread cellular damage through a number of secondary effects including rapid uptake of aminoglycosides via elevated proton-motive force (PMF), membrane damage and breakdown, oxidative stress, and hyperpolarisation of the membrane. Several factors associated with aminoglycoside entry have been shown to impact upon bacterial killing, and more recent work has revealed a complex relationship between metabolic states and the efficacy of different aminoglycosides. Hence, it is imperative to consider the environmental conditions and bacterial physiology and how this can impact upon aminoglycoside entry and potency. This mini-review seeks to discuss recent advances in this area and how this might affect the future use of aminoglycosides.

show abstract

Clinical Usefulness of Arbekacin

Cited by 11 publications

References 34 publications

Clinical Efficacy and Safety of Arbekacin against Pneumonia in Febrile Neutropenia: A Retrospective Study in Patients with Hematologic Malignancies

Clinical Efficacy and Safety of Arbekacin against Pneumonia in Febrile Neutropenia: A Retrospective Study in Patients with Hematologic Malignancies

SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study

A mini-review: environmental and metabolic factors affecting aminoglycoside efficacy

Contact Info

Product

Resources

About